---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000056"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T19:40:41.045414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics monetizes Evrysdi royalties for up to $1.5B, pays off Blackstone debt

## Summary
- PTC receives $1.0B upfront for ~38% additional Evrysdi royalty; total ~81% sold to Royalty Pharma.
- PTC can sell remaining royalty for up to $500M via puts through Dec 2025; Royalty Pharma may call up to $250M.
- Proceeds to retire all Blackstone debt; Credit Agreement from Oct 2022 terminated.
- PTC retains all economics on up to $250M in commercial sales milestones for Evrysdi.

## SEC filing metadata
- accession: 0001070081-23-000056
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000056/0001070081-23-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000056/tmb-20231018x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000056
- JSON: https://secwatch.observer/filing/0001070081-23-000056.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.